Literature DB >> 34962495

CORR Insights®: Is Metformin Use Associated with Prolonged Overall Survival In Patients with Soft Tissue Sarcoma? A SEER-Medicare Study.

Joel L Mayerson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34962495      PMCID: PMC8923598          DOI: 10.1097/CORR.0000000000002091

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  11 in total

1.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

2.  Is Metformin Use Associated with Prolonged Overall Survival in Patients with Soft Tissue Sarcoma? A SEER-Medicare Study.

Authors:  Ian D Hutchinson; Ashar Ata; Matthew R DiCaprio
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

Review 3.  Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.

Authors:  Jared L Harwood; John H Alexander; Joel L Mayerson; Thomas J Scharschmidt
Journal:  Orthop Clin North Am       Date:  2015-08-11       Impact factor: 2.472

4.  Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response.

Authors:  Vanessa E Zannella; Alan Dal Pra; Hala Muaddi; Trevor D McKee; Shawn Stapleton; Jenna Sykes; Rachel Glicksman; Selim Chaib; Paul Zamiara; Michael Milosevic; Bradly G Wouters; Robert G Bristow; Marianne Koritzinsky
Journal:  Clin Cancer Res       Date:  2013-10-18       Impact factor: 12.531

5.  Metformin use and improved response to therapy in esophageal adenocarcinoma.

Authors:  Heath D Skinner; Matthew R McCurdy; Alfredo E Echeverria; Steven H Lin; James W Welsh; Michael S O'Reilly; Wayne L Hofstetter; Jaffer A Ajani; Ritsuko Komaki; James D Cox; Vlad C Sandulache; Jeffrey N Myers; Thomas M Guerrero
Journal:  Acta Oncol       Date:  2012-09-05       Impact factor: 4.089

6.  Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.

Authors:  Aaron R Weiss; Yen-Lin Chen; Thomas J Scharschmidt; Yueh-Yun Chi; Jing Tian; Jennifer O Black; Jessica L Davis; Julie C Fanburg-Smith; Eduardo Zambrano; James Anderson; Robin Arens; Odion Binitie; Edwin Choy; Justin W Davis; Andrea Hayes-Jordan; Simon C Kao; Mark L Kayton; Sandy Kessel; Ruth Lim; William H Meyer; Lynn Million; Scott H Okuno; Andrew Ostrenga; Marguerite T Parisi; Daniel A Pryma; R Lor Randall; Mark A Rosen; Mary Schlapkohl; Barry L Shulkin; Ethan A Smith; Joel I Sorger; Stephanie Terezakis; Douglas S Hawkins; Sheri L Spunt; Dian Wang
Journal:  Lancet Oncol       Date:  2020-07-20       Impact factor: 41.316

7.  Prophylactic antibiotic regimens in tumour surgery (PARITY): a pilot multicentre randomised controlled trial.

Authors: 
Journal:  Bone Joint Res       Date:  2015-09       Impact factor: 5.853

Review 8.  Anti-tumor activity of metformin: from metabolic and epigenetic perspectives.

Authors:  Xilan Yu; Wuxiang Mao; Yansheng Zhai; Chong Tong; Min Liu; Lixin Ma; Xiaolan Yu; Shanshan Li
Journal:  Oncotarget       Date:  2017-01-17

Review 9.  Metformin as a Therapeutic Target in Endometrial Cancers.

Authors:  Teresa Y Lee; Ubaldo E Martinez-Outschoorn; Russell J Schilder; Christine H Kim; Scott D Richard; Norman G Rosenblum; Jennifer M Johnson
Journal:  Front Oncol       Date:  2018-08-28       Impact factor: 6.244

10.  The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances.

Authors:  Pouya Saraei; Ilia Asadi; Muhammad Azam Kakar; Nasroallah Moradi-Kor
Journal:  Cancer Manag Res       Date:  2019-04-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.